These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 16205065)

  • 1. Cutaneous adverse events of biological therapy for psoriasis: review of the literature.
    Thielen AM; Kuenzli S; Saurat JH
    Dermatology; 2005; 211(3):209-17. PubMed ID: 16205065
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adverse reactions during biological drug therapy in psoriasis:clinical series and a review of the literature.
    Montesu MA; Addis GM; Satta R; Cottoni F
    G Ital Dermatol Venereol; 2011 Aug; 146(4):273-81. PubMed ID: 21785393
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Biologic therapy for psoriasis: an update on the tumor necrosis factor inhibitors infliximab, etanercept, and adalimumab, and the T-cell-targeted therapies efalizumab and alefacept.
    Weinberg JM; Bottino CJ; Lindholm J; Buchholz R
    J Drugs Dermatol; 2005; 4(5):544-55. PubMed ID: 16167412
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cutaneous adverse effects of biological therapies for psoriasis.
    Roé E; Puig L; Corella F; García-Navarro X; Alomar A
    Eur J Dermatol; 2008; 18(6):693-9. PubMed ID: 18955203
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [New systemic treatments for psoriasis: etanercept, infliximab, adalimumab, efalizumab and alefacept].
    Bos WE; Thio HB; Neumann HA; van der Fits L; Prens EP
    Ned Tijdschr Geneeskd; 2006 May; 150(19):1065-70. PubMed ID: 16733982
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Biological agents in the treatment of psoriasis.
    Tzu J; Krulig E; Cardenas V; Kerdel FA
    G Ital Dermatol Venereol; 2008 Oct; 143(5):315-27. PubMed ID: 18833073
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Biologic therapy for psoriasis--the first wave: infliximab, etanercept, efalizumab, and alefacept.
    Weinberg JM; Saini R; Tutrone WD
    J Drugs Dermatol; 2002 Dec; 1(3):303-10. PubMed ID: 12851990
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A review of biologic treatments for psoriasis with emphasis on infliximab.
    Pirzada S; Tomi Z; Gulliver W
    Skin Therapy Lett; 2007 Apr; 12(3):1-4. PubMed ID: 17487347
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Onychomycosis in patients of nail psoriasis on biologic therapy: a randomized, prospective open label study comparing Etanercept, Infliximab and Adalimumab.
    Al-Mutairi N; Nour T; Al-Rqobah D
    Expert Opin Biol Ther; 2013 May; 13(5):625-9. PubMed ID: 23527597
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adverse events resulting in withdrawal of biologic therapy for psoriasis in real-world clinical practice: A Canadian multicenter retrospective study.
    Kim WB; Marinas JE; Qiang J; Shahbaz A; Greaves S; Yeung J
    J Am Acad Dermatol; 2015 Aug; 73(2):237-41. PubMed ID: 26026334
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Adverse events during biological therapy -- focusing on dermatological side-effects].
    Nagy G; Lukács K; Sziray A; Fazekas K; Florián A; Tamási L; Károlyi Z
    Orv Hetil; 2011 Feb; 152(6):212-20. PubMed ID: 21278026
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Biologic therapy: a new and promising option to treat psoriasis].
    Espinoza-González NA; Herz-Ruelas M; Ocampo-Candiani J; González-Soto R
    Rev Med Inst Mex Seguro Soc; 2008; 46(4):405-14. PubMed ID: 19213212
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A mechanism-based classification of dermatologic reactions to biologic agents used in the treatment of cutaneous disease: Part 2.
    Bremmer M; Deng A; Gaspari AA
    Dermatitis; 2009; 20(5):243-56. PubMed ID: 19807998
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Biologicals in the treatment of psoriasis.
    Boker A; Kimball AB; Rolz-Cruz G
    Curr Opin Investig Drugs; 2007 Nov; 8(11):939-46. PubMed ID: 17979028
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Relevance of laboratory investigations in monitoring patients with psoriasis on etanercept or adalimumab.
    van Lümig PP; Driessen RJ; Roelofs-Thijssen MA; Boezeman JB; van de Kerkhof PC; de Jong EM
    Br J Dermatol; 2011 Aug; 165(2):375-82. PubMed ID: 21428975
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Monoclonal antibodies in dermatological practice].
    Rudnicka L; Szymańska E; Oledzka E; Olszewska M
    Pol Merkur Lekarski; 2005 Dec; 19(114):839-42. PubMed ID: 16521437
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Biologic therapies in psoriasis: a new therapeutic approach.
    Gisondi P; Girolomoni G
    Autoimmun Rev; 2007 Sep; 6(8):515-9. PubMed ID: 17854741
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost effectiveness of biologic therapies for plaque psoriasis.
    Ahn CS; Gustafson CJ; Sandoval LF; Davis SA; Feldman SR
    Am J Clin Dermatol; 2013 Aug; 14(4):315-26. PubMed ID: 23696234
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tumor necrosis factor antagonists in the therapy of psoriasis.
    Mössner R; Schön MP; Reich K
    Clin Dermatol; 2008; 26(5):486-502. PubMed ID: 18755367
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Biological therapy and nail psoriasis.
    Lawry M
    Dermatol Ther; 2007; 20(1):60-7. PubMed ID: 17403261
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.